Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 10 of 10 entries
View as:

Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC)

Phase: N/A Priority: Normal
NCT ID: NCT03769467 Org: User:
Start: 02/19/19 End: 08/19/21 Due: 08/19/22

Phase 1/2 Study to Evaluate the Safety and Efficacy of ATA188 in Subjects With Progressive Multiple Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT03283826 Org: User:
Start: 10/19/17 End: 01/17/24 Due: 01/17/25

Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT00002663 Org: User:
Start: 03/31/95 End: 07/31/19 Due: 07/31/20

A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases

Phase: N/A Priority: Normal
NCT ID: NCT04554914 Org: User:
Start: 07/14/21 End: 05/31/29 Due: 05/31/30

Therapeutic Effects of Epstein-Barr Virus Immune T-Lymphocytes Derived From a Normal HLA-Compatible Or Partially-Matched Third-Party Donor in the Treatment of EBV Lymphoproliferative Disorders and EBV-Associated Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01498484 Org: User:
Start: 12/31/11 End: 07/31/19 Due: 07/31/20

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Systemic Lupus Erythematosus

Phase: N/A Priority: Normal
NCT ID: NCT06429800 Org: User:
Start: 04/16/25 End: 04/16/25 Due: 04/16/26

Expanded Access Protocol of ATA230 (Third-Party Donor-Derived CMV-CTLs) for the Treatment of CMV Viremia or Disease

Phase: N/A Priority: Normal
NCT ID: NCT03010332 Org: User:
Start: - End: - Due: -

A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT06256484 Org: User:
Start: 09/06/24 End: 03/30/25 Due: 03/30/26

Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT03394365 Org: User:
Start: 12/29/17 End: 06/30/27 Due: 06/30/28

Expanded Access Protocol for Tabelecleucel for Patients With Epstein-Barr Virus-Associated Viremia or Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT02822495 Org: User:
Start: - End: - Due: -